These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31233255)

  • 1. Ziconotide for spinal cord injury-related pain.
    Brinzeu A; Berthiller J; Caillet JB; Staquet H; Mertens P
    Eur J Pain; 2019 Oct; 23(9):1688-1700. PubMed ID: 31233255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPIDOL study protocol for the assessment of intrathecal ziconotide antalgic efficacy for severe refractory neuropathic pain due to spinal cord lesions.
    Brinzeu A; Berthiller J; Perreton N; Subtil F; Gervaise C; Luaute J; Mertens P;
    Trials; 2024 Sep; 25(1):595. PubMed ID: 39244617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.
    Wermeling DP; Berger JR
    Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report.
    Saulino M
    Spinal Cord; 2007 Nov; 45(11):749-52. PubMed ID: 17310258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ziconotide: an innovative alternative for intense chronic neuropathic pain].
    Valía-Vera JC; Villanueva VL; Asensio-Samper JM; López-Alarcón MD; de Andrés JA
    Rev Neurol; 2007 Dec 1-15; 45(11):665-9. PubMed ID: 18050098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziconotide Trialing by Intrathecal Bolus Injections: An Open-Label Non-Randomized Clinical Trial in Postoperative/Posttraumatic Neuropathic Pain Patients Refractory to Conventional Treatment.
    Bäckryd E; Sörensen J; Gerdle B
    Neuromodulation; 2015 Jul; 18(5):404-13. PubMed ID: 25879804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report.
    Horazeck C; Huh AS; Huh BK
    Pain Pract; 2015 Mar; 15(3):E34-9. PubMed ID: 25565390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal ziconotide for neuropathic pain: a review.
    Rauck RL; Wallace MS; Burton AW; Kapural L; North JM
    Pain Pract; 2009; 9(5):327-37. PubMed ID: 19682321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being, and Pain Catastrophizing.
    Shao MM; Khazen O; Hellman A; Czerwinski M; Dentinger R; DiMarzio M; Gillogly M; Hadanny A; Argoff C; Pilitsis JG
    World Neurosurg; 2021 Jan; 145():e340-e347. PubMed ID: 33096281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study.
    Deer TR; Kim C; Bowman R; Tolentino D; Stewart C; Tolentino W
    Pain Physician; 2009; 12(4):E291-6. PubMed ID: 19668287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
    Sanford M
    CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
    Pope JE; Deer TR
    Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Outcomes Using Intrathecal Drug Delivery Systems in Complex Regional Pain Syndrome.
    Herring EZ; Frizon LA; Hogue O; Mejia JU; Rosenquist R; Bolash RB; Machado AG; Nagel SJ
    Pain Med; 2019 Mar; 20(3):515-520. PubMed ID: 29889241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ziconotide for treatment of severe chronic pain.
    Schmidtko A; Lötsch J; Freynhagen R; Geisslinger G
    Lancet; 2010 May; 375(9725):1569-77. PubMed ID: 20413151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziconotide Combination Intrathecal Therapy for Noncancer Pain Is Limited Secondary to Delayed Adverse Effects: A Case Series With a 24-Month Follow-Up.
    Hayek SM; Hanes MC; Wang C; Veizi IE
    Neuromodulation; 2015 Jul; 18(5):397-403. PubMed ID: 25655991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziconotide intrathecal delivery as treatment for secondary therapeutic failure of motor cortex stimulation after 6 years.
    Voirin J; Darie I; Fischer D; Simon A; Rohmer-Heitz I; Proust F
    Neurochirurgie; 2016 Oct; 62(5):284-288. PubMed ID: 27771111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.